<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744379</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-125</org_study_id>
    <nct_id>NCT01744379</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study in Japanese</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the safety, tolerability, and serum uric acid lowering effect of
      lesinurad in healthy Japanese males to allow comparison with the Western population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While there is extensive clinical experience with lesinurad in the Western population, it is
      recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose
      response in different ethnic populations. The purpose of this study is to explore the safety,
      tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of
      lesinurad in healthy Japanese males, and to allow comparison of these parameters with the
      Western population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory Parameters</measure>
    <time_frame>5 to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of lesinurad from plasma and urine in terms of AUC, tmax, cmax and t1/2.</measure>
    <time_frame>Day -1 through 12</time_frame>
    <description>AUC: area under the plasma concentration time curve from zero to 24 hours post dose and from zero to infinity; tmax: time to maximum plasma concentration; cmax: maximum observed plasma concentration t1/2: terminal elimination half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) profile of lesinurad from serum and urine in terms of sUA concentration, renal clearance, urine uric acid excretion, and fractional excretion.</measure>
    <time_frame>Day 1 through 12</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg lesinurad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg lesinurad or placebo fasted and fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad</intervention_name>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_label>600 mg lesinurad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>200 mg lesinurad</arm_group_label>
    <arm_group_label>400 mg lesinurad</arm_group_label>
    <arm_group_label>100 mg lesinurad</arm_group_label>
    <arm_group_label>50 mg lesinurad</arm_group_label>
    <arm_group_label>600 mg lesinurad</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand the study procedures, the risks involved and willing to provide
             written Informed Consent before the first study related activity.

          -  Healthy adult subjects born in Japan

          -  All laboratory parameters should be within normal limits or considered not clinically
             significant by the investigator.

          -  Screening serum uric acid level &gt;= 4.5 mg/dL.

          -  Subjects must be free of any clinically significant disease that requires a
             physician's care and/or would interfere with study evaluations or procedures.

          -  Subject does not have clinically relevant abnormalities in blood pressure, heart rate,
             body temperature, and respiratory rate, as per the Investigator's judgment.

        Exclusion Criteria:

          -  Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2).

          -  Positive test for active Hepatitis B or Hepatitis C infection.

          -  History of kidney stones.

          -  Undergone major surgery within 3 months of Day 1.

          -  Subject has received the last dose of an investigational drug (or treatment with a
             medical device) within 30 days or 5 half-lives (whichever is longer) of the
             investigational drug prior to Day 1 or are currently participating in another study of
             an investigational drug (or medical device).

          -  Prior exposure to lesinurad (RDEA594) or RDEA806.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Bradley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

